Preliminary
How CMV Drives Aging in HIV Patients—And What We Can Do About It

CMV is a hidden driver of accelerated aging in people with HIV, but it's druggable: early trials of antivirals and vaccines show promise, and larger studies could transform care. This …

35 /100
This is a narrative review, not original research—no new data or patient cohort presented. The interventions discussed (letermovir, vaccines) are …
Preliminary
Can senolytic drugs restore fertility in female mice with fatty liver disease?

A mouse study suggests senolytic drugs might improve fertility in females with fatty liver disease by reducing cellular aging in the ovaries, though they don't actually fix the liver disease. …

39 /100
Small sample size typical of mouse studies limits statistical power and generalizability. No mention of sample size calculation or power …
Preliminary
Can we reverse aging by partially reprogramming cells?

Partial reprogramming is a promising concept for reversing aging at the cellular level, with encouraging early results in animals. However, it remains largely unproven in humans—think of this as a …

36 /100
This is a review paper with no original data, so it synthesizes prior work rather than presenting new evidence. Zero …
Preliminary
Rapamycin reduces age-related motor decline in mice, especially in females

Rapamycin preserved movement and motor control in aging mice, particularly in females, seemingly by reducing cellular stress in the brain. This is encouraging but still preliminary—animal findings require human testing …

47 /100
Recent publication (March 2026) with zero citations yet—replication status unknown. No mention of data availability statement, open access status, or …
Preliminary
Reversing cell aging in stem cells using temporary genetic reprogramming

This is a promising proof-of-concept for temporarily 'resetting' aging in stem cells using non-integrating viral vectors, but it's early-stage laboratory work. Before this can help patients, researchers need to test …

39 /100
In vitro study only—no animal or human data. Long-term safety and efficacy unknown. Use of SV40T oncogene raises tumorigenicity concerns, …
Preliminary
Natural compound DMB reduces cellular aging by activating DNA repair protein FEN1

This is a solid proof-of-concept study showing a natural compound can reduce cellular aging markers in the lab and extend lifespan in worms—promising enough to justify further study, but too …

36 /100
First-report study with zero citations (recent publication, but no independent replication yet). Single human cell line tested, no primary cells …
Preliminary
How chemical marks on RNA control telomeres and aging

This thoughtful review proposes that chemical tags on RNA—not just DNA mutations—are key regulators of telomere aging, and highlights promising research directions. However, it presents no new experimental proof; the …

28 /100
This is a review article with no primary data, so no sample size, no experiments, and no replication data exist. …
Preliminary
How bats' virus defenses may hold secrets to extreme longevity

This early-stage work suggests that bats' extreme longevity may stem from evolved adaptations that let them tolerate viruses peacefully—and these same genes protect against cancer. It's an intriguing hypothesis that …

29 /100
Preprint status (not peer-reviewed). Small sample size (8 species, ~50 individuals estimated). Functional validation limited to in vitro cell cultures—no …